HUTCHMED (China) (HCM) Change in Receivables (2020 - 2021)

HUTCHMED (China)'s (HCM) quarterly Change in Receivables came in at -$6.5 million in Q1 2021, down 480.47% year-on-year from $1.7 million in Q1 2020, and down 480.47% on a QoQ basis from $1.7 million in Q1 2020.

HUTCHMED (China) (HCM) Change in Receivables (2020 - 2021) Analysis & Trends

HUTCHMED (China) (HCM) has 2 years of Change in Receivables data on file, last reported at -$6.5 million in Q1 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn -78.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 106.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -621.82 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -38.20 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 126.30 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 81.40 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -
10 HUTCHMED (China) 241.90 Mn 243.61 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 -6.53 Mn
Mar 31, 2021 -6.53 Mn
Mar 31, 2020 1.72 Mn
Mar 31, 2020 1.72 Mn